By Diagnostics World Team
April 24, 2026 | Last week, Mount Sinai Health System announced that it has adopted SOPHiA DDM, SOPHiA GENETICS’ AI-powered platform that analyzes complex genomic and multimodal data, producing real-time, actionable insights for hospital, laboratory, and biopharma institutions across the world. Mount Sinai’s molecular pathology team will use the SOPHiA DDM for Blood Cancers and SOPHiA DDM for Solid Tumors applications to enhance next-generation sequencing for blood cancers and solid tumors.
“Leveraging SOPHiA DDM has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care,” said Jane Houldsworth, Ph.D., director of molecular oncology pathology of the Mount Sinai Health System, in a press release.
Engineered for early detection and interpretation of a broad range of complex genomic variants, SOPHiA DDM improves workflow efficiency by consolidating critical stages in the analysis pipeline and cutting down on manual interpretation time. This collaboration enables Mount Sinai to accelerate precision medicine, reduce operational burden, and get patients the care they need sooner. It also highlights the growing need for democratizing data-driven medicine that can deliver solutions and empower healthcare institutions to expand genomic testing and improve patient outcomes.
This announcement builds on a milestone achieved in February, when SOPHiA DDM for Enhanced Exome was adopted by two unnamed U.S. healthcare systems. SOPHiA DDM for Enhanced Exome is an AI-driven analytics application that analyzes more than 20,000 genes and allows deeper exploration of clinically important regions.